Matthew A. Gubens

20.9k total citations · 2 hit papers
100 papers, 4.3k citations indexed

About

Matthew A. Gubens is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Matthew A. Gubens has authored 100 papers receiving a total of 4.3k indexed citations (citations by other indexed papers that have themselves been cited), including 76 papers in Oncology, 65 papers in Pulmonary and Respiratory Medicine and 21 papers in Cancer Research. Recurrent topics in Matthew A. Gubens's work include Lung Cancer Treatments and Mutations (60 papers), Cancer Immunotherapy and Biomarkers (43 papers) and Lung Cancer Diagnosis and Treatment (28 papers). Matthew A. Gubens is often cited by papers focused on Lung Cancer Treatments and Mutations (60 papers), Cancer Immunotherapy and Biomarkers (43 papers) and Lung Cancer Diagnosis and Treatment (28 papers). Matthew A. Gubens collaborates with scholars based in United States, Taiwan and South Korea. Matthew A. Gubens's co-authors include Amita Patnaik, Leena Gandhi, Shirish M. Gadgeel, James Stevenson, Lecia V. Sequist, Hossein Borghaei, Corey J. Langer, James Chih‐Hsin Yang, Steven Powell and Shadia I. Jalal and has published in prestigious journals such as Journal of Clinical Oncology, Journal of the American College of Cardiology and PLoS ONE.

In The Last Decade

Matthew A. Gubens

97 papers receiving 4.2k citations

Hit Papers

Carboplatin and pemetrexe... 2016 2026 2019 2022 2016 2021 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study
    2016 1.1k citations Corey J. Langer, Shirish M. Gadgeel et al. The Lancet Oncology profile →
  2. Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1–Positive Advanced NSCLC
    2021 201 citations Edward B. Garon, Matthew A. Gubens et al. Journal of Thoracic Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Matthew A. Gubens United States 30 3.4k 2.3k 754 565 524 100 4.3k
Á. Artal Spain 20 3.2k 0.9× 2.5k 1.1× 607 0.8× 878 1.6× 606 1.2× 82 4.3k
Peter Langmuir United States 30 1.8k 0.5× 1.6k 0.7× 888 1.2× 1.3k 2.3× 507 1.0× 56 4.7k
Patrick M. Forde United States 40 4.0k 1.2× 2.7k 1.2× 1.1k 1.5× 934 1.7× 645 1.2× 186 5.7k
Thomas Brodowicz Austria 28 2.4k 0.7× 2.0k 0.9× 216 0.3× 585 1.0× 468 0.9× 126 3.4k
Shunichi Sugawara Japan 36 4.2k 1.2× 3.5k 1.5× 448 0.6× 1.1k 1.9× 548 1.0× 209 5.4k
Bilal Piperdi United States 35 3.9k 1.1× 2.8k 1.2× 493 0.7× 821 1.5× 518 1.0× 119 5.0k
Mark Kozloff United States 36 3.2k 0.9× 1.7k 0.7× 299 0.4× 1.3k 2.3× 702 1.3× 125 4.7k
Emmanuel Quinaux Belgium 18 4.2k 1.2× 1.3k 0.6× 560 0.7× 656 1.2× 768 1.5× 37 4.9k
Achim Rittmeyer United States 26 4.9k 1.4× 3.5k 1.5× 1.1k 1.4× 593 1.0× 687 1.3× 91 5.7k
Vincenzo Adamo Italy 27 2.4k 0.7× 2.2k 1.0× 174 0.2× 1.0k 1.8× 699 1.3× 118 3.8k

Countries citing papers authored by Matthew A. Gubens

Since Specialization
Citations

This map shows the geographic impact of Matthew A. Gubens's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew A. Gubens with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew A. Gubens more than expected).

Fields of papers citing papers by Matthew A. Gubens

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthew A. Gubens. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew A. Gubens. The network helps show where Matthew A. Gubens may publish in the future.

Co-authorship network of co-authors of Matthew A. Gubens

This figure shows the co-authorship network connecting the top 25 collaborators of Matthew A. Gubens. A scholar is included among the top collaborators of Matthew A. Gubens based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matthew A. Gubens. Matthew A. Gubens is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Middha, Pooja, Rohit Thummalapalli, Zoe Quandt, et al.. (2025). Germline prediction of immune checkpoint inhibitor discontinuation for immune-related adverse events. Journal for ImmunoTherapy of Cancer. 13(3). e011273–e011273. 1 indexed citations
2.
Gubens, Matthew A., Shiraj Sen, Mohamad A. Salkeni, et al.. (2024). P2.10A.02 Phase 1/1b Trial of MBRC-101, An Anti-EphA5 Monomethyl Auristatin (MMAE) Antibody Drug Conjugate, In Advanced Refractory Solid Tumors. Journal of Thoracic Oncology. 19(10). S243–S244. 1 indexed citations
3.
Park, Henry S., Andreas Rimner, Arya Amini, et al.. (2024). Appropriate Use Criteria (AUC) for the Management of Non-Small Cell Lung Cancer in a Central/Ultra-Central Location: Guidelines from the American Radium Society. Journal of Thoracic Oncology. 19(12). 1640–1653. 3 indexed citations
4.
5.
Hellyer, Jessica A., Matthew A. Gubens, Kristen Cunanan, et al.. (2019). Phase II trial of single agent amrubicin in patients with previously treated advanced thymic malignancies. Lung Cancer. 137. 71–75. 11 indexed citations
6.
Burudpakdee, Chakkarin, et al.. (2018). Economic impact of preventing brain metastases with alectinib in ALK-positive non-small cell lung cancer. Lung Cancer. 119. 103–111. 26 indexed citations
7.
Borghaei, Hossein, Corey J. Langer, Shirish M. Gadgeel, et al.. (2018). 24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non–Small Cell Lung Cancer. Journal of Thoracic Oncology. 14(1). 124–129. 169 indexed citations
8.
Illei, Peter B., William B. Wong, Ning Wu, et al.. (2018). ALK Testing Trends and Patterns Among Community Practices in the United States. JCO Precision Oncology. 2(2). 1–11. 40 indexed citations
9.
Jönsson, Vanessa D., Luping Lin, Saurabh Asthana, et al.. (2017). Novel computational method for predicting polytherapy switching strategies to overcome tumor heterogeneity and evolution. Scientific Reports. 7(1). 44206–44206. 28 indexed citations
10.
Premasekharan, Gayatri, Elizabeth Gilbert, Ross A. Okimoto, et al.. (2016). An improved CTC isolation scheme for pairing with downstream genomics: Demonstrating clinical utility in metastatic prostate, lung and pancreatic cancer. Cancer Letters. 380(1). 144–152. 21 indexed citations
11.
Langer, Corey J., Shirish M. Gadgeel, Hossein Borghaei, et al.. (2016). Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. The Lancet Oncology. 17(11). 1497–1508. 1071 indexed citations breakdown →
12.
Wakelee, Heather A., Sukhmani K. Padda, Matthew Burns, et al.. (2015). Oral 1.01: Phase II trial of amrubicin in patients with previously treated advanced thymic malignancies. Journal of Thoracic Disease. 7(3). 101. 1 indexed citations
13.
Wakelee, Heather A., Sukhmani K. Padda, Matthew Burns, et al.. (2015). Phase II trial of single agent amrubicin (A) in patients (pts) with previously treated advanced thymic malignancies (TM).. Journal of Clinical Oncology. 33(15_suppl). 7580–7580. 5 indexed citations
14.
Smith, David C., Peter D. Eisenberg, Georgy M. Manikhas, et al.. (2014). A Phase I Dose Escalation and Expansion Study of the Anticancer Stem Cell Agent Demcizumab (Anti-DLL4) in Patients with Previously Treated Solid Tumors. Clinical Cancer Research. 20(24). 6295–6303. 123 indexed citations
15.
16.
Kunz, Pamela L., Matthew A. Gubens, George A. Fisher, et al.. (2012). Long-Term Survivors of Gastric Cancer: A California Population-Based Study. Journal of Clinical Oncology. 30(28). 3507–3515. 104 indexed citations
17.
Gubens, Matthew A.. (2012). Treatment Updates in Advanced Thymoma and Thymic Carcinoma. Current Treatment Options in Oncology. 13(4). 527–534. 11 indexed citations
18.
Neal, Joel W., Matthew A. Gubens, & Heather A. Wakelee. (2011). Current Management of Small Cell Lung Cancer. Clinics in Chest Medicine. 32(4). 853–863. 28 indexed citations
19.
Gubens, Matthew A. & Heather A. Wakelee. (2010). Docetaxel in the treatment of non-small cell lung carcinoma: an update and analysis. Dove Medical Press (Taylor and Francis Group). 2 indexed citations
20.
Heidenreich, Paul A., Matthew A. Gubens, Gregg C. Fonarow, et al.. (2004). Cost-effectiveness of screening with B-type natriuretic peptide to identify patients with reduced left ventricular ejection fraction. Journal of the American College of Cardiology. 43(6). 1019–1026. 139 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Á. Artal Breakdown of academic impact, for papers by Peter Langmuir Breakdown of academic impact, for papers by Patrick M. Forde Breakdown of academic impact, for papers by Thomas Brodowicz Breakdown of academic impact, for papers by Shunichi Sugawara Breakdown of academic impact, for papers by Bilal Piperdi Breakdown of academic impact, for papers by Mark Kozloff Breakdown of academic impact, for papers by Emmanuel Quinaux Breakdown of academic impact, for papers by Achim Rittmeyer Breakdown of academic impact, for papers by Vincenzo Adamo
Rankless by CCL
2026